Biotech Traders threadMany of the comments on the main bio threads are about day to day trading activity. This thread has been created so as to cut down the quantity of posts on the main bio threads, plus give traders their own space to bat stuff around. There is no thread leader as the thoughts are momentary. So it works like a ticker tape as do the SP’s.
Enjoy
PS Anyone use Candlesticks?
This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.
$PACB Pacific Biosciences Benny Hill queried on a teaser from Oxford. Small company about to zoom with revolutionary bread slicer etc and 4150% increase to make everyone rich. I think this is it.
Pacific Biosciences matches the teaser in most particulars…their specialty, annual volume, stock price, partnership with Roche, and importantly a sole source provider award from CDC. I saw an “Intent to award” press release from CDC but did not see that the award has been made, maybe it’s about to hit.
I didn’t confirm a few of the teased facts, the one I am most concerned with is that the teaser said the company has 161 patents and is working on a personal diagnostic machine, I did not see evidence of this on the PACB website, so I’m not 100% sure they are the company, only 90% sure.
The institutional ownership is good 60% or so and short interest is about 16%.
Annual sales 57 MM. The stock has meandered around lately, closed $5.96.
They just awarded a whole bunch of directors with 25,000 stock options each, strike 5.80,
these can be exercised over a one year period starting June.
Looks interesting to me, although I have no positions in any device or equipment makers,
so this is a new area for me. Would like some opinions on this stock.
$PACB…they have the patents… couple of hundred between the granted patents and the
applications. So now I’m 99.9% sure these are the guys in the Oxford tease.
PACB-HN, Thanks for the sleuthing…here’s Dr. KSS’s comments from the spreadsheet that HiPockets provides us (Thanks HiPockets we ‘precaite ya!): The CDC might want this company for pathogen sequencing, to which I say big whoop. A medical diagnostics company will not ever take on the valuation gushed about here, and several pre-IPO companies like Knome have better methods. Best2ALL!-Benjamin
http://www.stockgumshoe.com/reviews/oxford-club/lichtenfeld-i-see-a-4150-earnings-setup-in-this-7-biotech/
PTN- Palatin Supports FDA Advisory Committee’s Recommendation To Approve The First-Ever Treatment For Hypoactive Sexual Desire Disorder Best2ALL!-Benjamin
IPO’s FYI: Best2ALL!-Benjamin
IPO Scorecard: Update on Selected Initial Stock Offerings
1:29 pm ET June 5, 2015 (Dow Jones) Print
Company Symbol Percent Current Offer IPO Date*
Code Rebel Corp. CDRB 583% $34.13 $5.00 19-May-15
ATyr Pharma Inc. LIFE 83% $25.65 $14.00 7-May-15
Shopify Inc. SHOP 59% $27.10 $17.00 21-May-15
Collegium Pharmaceutical Inc. COLL 59% $19.12 $12.00 7-May-15
Fenix Parts Inc. FENX 41% $11.25 $8.00 14-May-15
David’s Tea Inc. DTEA 36% $25.89 $19.00 5-Jun-15
Bojangles’ Inc. BOJA 32% $25.05 $19.00 8-May-15
Fate Therapeutics Inc. FATE 25% $6.24 $5.00 21-May-15
EQT GP Holdings LP EQGP 17% $31.56 $27.00 12-May-15
Black Knight Financial Services Inc. BKFS 17% $28.57 $24.50 20-May-15
Evolent Health Inc. EVH 13% $19.28 $17.00 5-Jun-15
Baozun Inc. BZUN 9% $10.88 $10.00 21-May-15
Tallgrass Energy GP LP TEGP 9% $31.50 $29.00 7-May-15
Press Ganey Holdings Inc. PGND 6% $26.56 $25.00 21-May-15
EndoChoice GI 5% $15.71 $15.00 5-Jun-15
Arcadia Biosciences Inc. RKDA 0% $8.04 $8.00 15-May-15
Community Healthcare Trust Inc. CHCT 0% $19.05 $19.00 21-May-15
Fortress Transportation & Infrastructure FTAI 0% $16.93 $17.00 15-May-15
PennTex Midstream Partners LP PTXP -3% $19.33 $20.00 4-Jun-15
Jaguar Animal Health Inc. JAGX -6% $6.55 $7.00 13-May-15
BiondVax Pharmaceuticals Ltd. BVXV -11% $4.43 $5.00 12-May-15
*Date represents first day of trading
and current and upcoming IPO’s per TDAm
DTEA 06/05 $19.00 – 19.00
GI 06/05 $15.00 – 15.00
EVH 06/05 $17.00 – 17.00
PUB 06/08 $13.00 – 15.00
YECO 06/08 $6.25 – 7.25
AXON 06/11 $13.00 – 15.00
IVTY 06/11 $14.00 – 16.00
BITI 06/12 $14.82 – 14.82
PSWW 06/12 $9.00 – 11.00
WING 06/12 $12.00 – 14.00
SGYP-NEW YORK– Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced positive top-line results from the first of two pivotal phase 3 clinical trials evaluating the efficacy and safety of two different plecanatide treatment doses (3.0 mg and 6.0 mg), taken as a tablet once-a-day, in 1,346 adult patients with chronic idiopathic constipation (CIC).
Preliminary analysis of the data indicates that both plecanatide 3.0 mg and 6.0 mg doses met the study’s primary endpoint and demonstrated statistical significance in the proportion of patients in the intention-to-treat population who were durable overall responders compared to placebo during the 12-week treatment period (21.0% in 3.0 mg and 19.5% in 6.0 mg dose groups compared to 10.2% in placebo; p<0.001 for both doses). The durable overall responder endpoint is the current FDA endpoint required for US approval in CIC. Plecanatide would be the first drug approved for CIC using the more stringent regulatory requirement for durability in the response. Notably, plecanatide was safe and well tolerated at both doses; the most common adverse event was diarrhea, which occurred in 5.9% of patients in 3.0 mg and 5.5% of patients in 6.0 mg dose groups compared to 1.3% of placebo-treated patients. More here:
http://ir.synergypharma.com/press-releases/detail/1788 Best2All!-Benjamin
CRMD- CorMedix Inc. Receives Positive Feedback from FDA for Neutrolin(R) Clinical Trial Protocol for Oncology Patients PR Newswire Best2ALL!-Benjamin
Technical comments of some of our favorites:
$TRVN $FLKS $TRIL $XENE based on recent technical and price action, these look to me to be at good entry points on June 17. Plus Yellen stated stated status quo from the Fed.
Follow up on previous short term callouts: $ZFGN moved into the overhead congestion zone, IMO confirming an end to the previous intermediate downtrend; and ESPR moved up to $ 79.
Long all tickers except $XENE
AVXL-I wonder when gravity kicks in? Best2ALL!-Ben
AVXL- Castles Made Of Sand https://www.youtube.com/watch?v=NLx_7A_0RxA&list=RDNLx_7A_0RxA Enjoy the music Best2ALL!-Benjamin
Ben,
$AVXL looks like profit taking may have begun already today. Hit my sell point already so that was a nice return.
V/R
Tom
Congrats Tom…mo mo is a very powerful thing 🙂
AVXL-awarded MJFF grant: http://globenewswire.com/news-release/2015/08/10/759225/0/en/Anavex-Awarded-Grant-From-The-Michael-J-Fox-Foundation-for-Parkinson-s-Research.html
CAPN- http://globenewswire.com/news-release/2015/09/08/766567/10148463/en/Capnia-Acquires-Neonatal-Pulmonary-Resuscitation-Solutions-From-NeoForce-Group-Inc.html Best2ALL!-Ben
CAPN-up over 70%
NSPH- http://globenewswire.com/news-release/2015/09/08/766619/10148420/en/Nanosphere-Receives-FDA-Clearance-for-First-of-Its-Kind-Flexible-Respiratory-Pathogens-Test.html
SGNL- http://globenewswire.com/news-release/2015/09/08/766664/10147645/en/Signal-Genetics-and-Moffitt-Cancer-Center-Enter-Into-Sponsored-Research-Agreement-in-Multiple-Myeloma.html
Benzinga’s Top #PreMarket Gainers
8:09 am ET September 9, 2015 (Benzinga) Print
Akebia Therapeutics Inc (NASDAQ: AKBA) shares rose 82.46 percent to $14.25 in pre-market trading after announcing positive top-line results from a Phase 2 study of Vadadustat “in Dialysis Patients with Anemia Related to Chronic Kidney Disease.”
Vitae Pharmaceuticals Inc (NASDAQ: VTAE) shares jumped 22.95 percent to $9.75 in pre-market trading after making public the positive top-line results it achieved “from its Phase 1 single ascending dose clinical study of VTP-43742 in autoimmune disorders.”
AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) shares rose 16.38 percent to $4.76 in pre-market trading after the company reported that ARX-04 has met all endpoints in PIVOTAL Phase 3 study for moderate-to-severe acute pain. Best2ALL!-Ben
AQXP-One of 10 Stocks That Moved After Friday’s Market Close 2:00 pm ET September 12, 2015
Aquinox Pharmaceuticals Inc (NASDAQ: AQXP) is shaping up to be the biggest winner in Friday’s after-hours trading. The stock rose more than 20 percent since the bell rang, although no particular news seems to have triggered the surge. In fact, the rally looks more like a continuation of the 4.86 percent rise the stock experienced over the day.
September 11, 2015 5:02 pm ET
*UPDATE: Amended 13D Filing from Baker Bros. on Aquinox Pharma Shows 39.6% Stake
4:16 pm ET *Baker Bros Advisors Lp Buys 2,480,032 Of Aquinox Pharmaceuticals @$15.50/Share -Form 4 Benzinga
Aquinox Has 33% Upside As These Four Catalysts Come Near
9:22 am ET September 11, 2015 (Benzinga) Print
Aquinox Pharmaceuticals Inc (NASDAQ: AQXP) shares have lost 13 percent over the past month, trading far below their 52-week high of $55.75.
Canaccord Genuity’s Corey Davis maintained a Buy rating for the company, while raising the price target from $10 to $22.
The company is expected to launch a BPS/IC indication on its own, Davis said, estimating U.S. sales to grow from $13 million in 2019 to $273 million in 2025.
Earlier in June, AQX-1125’s Phase II LEADERSHIP trial in BPS/IC missed its primary endpoint of reduction in average daily pain after six weeks. On August 6, the company revealed “a preponderance of positive results from multiple pre-specified secondary endpoints that revived the stock — and our view on the chance for success,” analyst Corey Davis said.
In the report Canaccord Genuity noted the most clinically meaningful data points as:
Numerical separation from placebo for all pain endpoints as early as two weeks
Loss of efficacy was seen almost immediately in the two-week follow-up after six weeks of treatment
Statistically significant reduction in “maximum daily pain scores,” with the primary being “average daily pain”
Significantly reduced O’Leary-Sant ICSI/PI, a validated, patient reported outcome measure.
“So even though the trial technically failed, there’s plenty of supporting evidence to conclude that AQX-1125 has therapeutic potential in IBS/IC. We’ll know more after the meeting with FDA in Nov. As a result, we are now only including IBS/ IC in our model and assuming no partnership,” Davis wrote. Best-Ben
AQXP-up ~44% Happy Monday! Best2ALL!-Ben
XNPT- XenoPort, Inc. (NASDAQ: XNPT) shares rose 8.32 percent to $7.29 in pre-market trading after the company reported positive Phase 2 study results for XP23829 as a potential treatment for patients with psoriasis.
GWPH- http://globenewswire.com/news-release/2015/09/15/768364/10149367/en/GW-Pharmaceuticals-Announces-Positive-Proof-of-Concept-Data-in-Schizophrenia.html
ITCI- http://globenewswire.com/news-release/2015/09/16/768604/10149501/en/Intra-Cellular-Therapies-Announces-Positive-Top-Line-Results-From-the-First-Phase-3-Trial-of-ITI-007-in-Patients-With-Schizophrenia-and-Confirms-the-Unique-Pharmacology-of-ITI-007-.html Happy Humpday! Best-Ben
GERN- http://globenewswire.com/news-release/2015/09/16/768631/0/en/Geron-Announces-Initiation-of-Janssen-Phase-2-Clinical-Trial-of-Imetelstat-in-Myelofibrosis.html
PRTK- http://globenewswire.com/news-release/2015/09/17/768955/10149668/en/Paratek-s-Omadacycline-Demonstrates-Broad-Spectrum-Activity-in-Pathogens-Relevant-in-Skin-Infections-Community-Acquired-Pneumonia-and-Urinary-Tract-Infections.html
CEMP- http://globenewswire.com/news-release/2015/09/18/769296/10149824/en/FDA-Grants-Qualified-Infectious-Disease-Product-Designation-to-Taksta-TM-Cempra-s-Fusidic-Acid-Antibiotic.html
TCON- http://globenewswire.com/news-release/2015/09/18/769295/10149778/en/TRACON-Pharmaceuticals-Reports-Ongoing-Complete-Response-in-Choriocarcinoma-Patient-Treated-With-Company-s-TRC105-in-Compassionate-Use-Phase-2-Clinical-Trial-Conducted-at-Dana-Farb.html
CNAT- Today’s News, September 23, 2015 4:10 pm ET
*UDPATE: Conatus Pharma Said Trial on Emricasan Met Primary Endpoint for Clinically Meaningful, Statistically Significant Change from Baseline in HVPG, from Baseline in cCK18 Benzinga
4:08 pm ET *Conatus Pharma Shares to Resume Trade at 4:30 p.m. EDT Benzinga
4:03 pm ET *UPDATE: Conatus Pharma Says Emricasan Significantly Lowered Portal Pressure in Patients With Severe Portal Hypertension Benzinga
http://globenewswire.com/news-release/2015/09/23/770458/10150345/en/Conatus-Announces-Top-line-Results-From-Multicenter-Phase-2-Portal-Hypertension-Clinical-Trial-in-Patients-With-Liver-Cirrhosis.html